Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6623569 | 0.85 | RAB9A (0.42) | RAB9AHTT | |
| SCHEMBL9254620 | 0.84 | POLB (0.47) | POLBSMN1; SMN2LMNACA12CA1 | |
| SCHEMBL22798569 | 0.81 | POLB (0.44) | POLBSMN1; SMN2LMNACA12CA1 | |
| SCHEMBL8196306 | 0.81 | POLB (0.44) | POLBSMN1; SMN2LMNACA12CA1 | |
| SCHEMBL670165 | 0.80 | POLB (0.43) | POLBSMN1; SMN2LMNACA12CA1 | |
| SCHEMBL670164 | 0.80 | POLB (0.43) | POLBSMN1; SMN2LMNACA12CA1 | |
| SCHEMBL5567091 | 0.80 | POLB (0.43) | POLBSMN1; SMN2LMNACA12CA1 | |
| SCHEMBL15500843 | 0.79 | L3MBTL1 (0.48) | POLBSMN1; SMN2NPC1RAB9A | |
| SCHEMBL25325183 | 0.78 | NPC1 (0.43) | NPC1RAB9A | |
| SCHEMBL9823 | 0.76 | ALDH1A1 (0.40) | POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4655289-A1 | SINGLE-MOLECULE PEPTIDE SEQUENCING USING GUANIDINYLATING AGENTS | Glyphic Biotechnologies, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| CN-119522092-A | Multivalent molecule-based lipid nanoparticles for nucleic acid delivery | 比奥-特里普公司 | 2025-02-25 | — | — | CN | disclosed |
| WO-2024159162-A1 | SINGLE-MOLECULE PEPTIDE SEQUENCING USING GUANIDINYLATING AGENTS | GLYPHIC BIOTECHNOLOGIES, INC. (US) | 2024-08-02 | — | — | WO | disclosed |
| US-11935803-B2 | Resin composition, laminate, semiconductor wafer with resin composition layer, substrate for mounting semiconductor with resin composition layer and semiconductor device | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2024-03-19 | — | — | US | disclosed |
| WO-2023233042-A1 | POLYVALENT MOLECULE BASED LIPID NANOPARTICLES FOR NUCLEIC ACID DELIVERY | BIO-TRIP B.V. (NL) | 2023-12-07 | — | — | WO | disclosed |
| US-11788080-B2 | Modified cleavases, uses thereof and related kits | Encodia, Inc. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11788080-B2 | Modified cleavases, uses thereof and related kits | Encodia, Inc. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11782062-B2 | Kits for analysis using nucleic acid encoding and/or label | Encodia, Inc. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11782062-B2 | Kits for analysis using nucleic acid encoding and/or label | Encodia, Inc. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230257727-A1 | MODIFIED CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2023-08-17 | — | — | US | disclosed |
| CN-1744916-A | Preventive or remedy for diseases caused by hyperglycemia | KISSEI PHARMACEUTICAL (JP) | 2006-03-08 | — | — | CN | disclosed |
| US-20060035844-A1 | Preventive or remedy for diseases caused by hyperglycemia | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-02-16 | — | — | US | disclosed |
| EP-1609798-A1 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2005-12-28 | — | — | EP | disclosed |
| US-20050272669-A1 | Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2005-12-08 | — | — | US | disclosed |
| EP-1568380-A1 | PREVENTIVE OR REMEDY FOR DISEASES CAUSED BY HYPERGLYCEMIA | Kissei Pharmaceutical Co., Ltd. (JP) | 2005-08-31 | — | — | EP | disclosed |
| EP-1548024-A1 | PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2005-06-29 | — | — | EP | disclosed |
| EP-1373216-B1 | 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY | SOLVAY PHARM BV (NL) | 2004-12-15 | — | — | EP | disclosed |
| CN-1486301-A | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity | ������ҩ������˾ | 2004-03-31 | — | — | CN | disclosed |
| US-6476060-B2 | DRUG ABUSE; PSYCHOLOGICAL DISORDERS; GASTROINTESTINAL DISORDERS; CARDIOVASCUALR DISORDERS | SOLVAY PHARMACEUTICALS, B.V. (NL) | 2002-11-05 | — | — | US | disclosed |
| US-20010053788-A1 | 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | SOLVAY PHARMACEUTICALS B.V. | 2001-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010053788-A1 | 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | CNR1, CNR2, CBR3 | POLB 4164/4885SMN1; SMN2 4520/4885LMNA 4585/4885 |
| US-20050272669-A1 | Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | UGGT1, GCKR, SLC5A1 | POLB 4523/4885SMN1; SMN2 4382/4885LMNA 2896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.